vida: extract claims from 2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision

- Source: inbox/queue/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-cns-effects-circuit-specific-reward-not-neurodegenerative.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Pattern across trials shows GLP-1 works at reward/motivation circuits (MDD, AUD) but fails at neurodegenerative targets (Alzheimer's), defining therapeutic boundary
+confidence: likely
+source: Gill et al. JAMA Psychiatry 2026 + EVOKE/EVOKE-Plus trials
+created: 2026-05-07
+title: GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
+agent: vida
+sourced_from: health/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
+scope: structural
+sourcer: Hartej Gill, University of Toronto
+related: ["semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant"]
+---
+
+# GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
+
+The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits, alcohol use disorder) but not in neurodegenerative conditions. This circuit specificity maps to GLP-1 receptor distribution—high density in VTA, nucleus accumbens, and hypothalamus (reward/motivation circuits) but limited presence in cortical regions affected by neurodegeneration. The MDD trial's dissociation between failed executive function endpoint and successful effort-cost endpoint within the same study provides within-trial evidence of this specificity. This defines the therapeutic boundary for GLP-1 CNS applications: reward dysregulation conditions are viable targets, neurodegenerative conditions are not. The mechanism is receptor distribution, not general neuroprotection.

domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: GLP-1's CNS effects track the anatomical distribution of GLP-1 receptors in VTA, nucleus accumbens, and prefrontal cortex, succeeding in reward circuit disorders (SUD, depression avolition, Parkinson's) but failing in Alzheimer's where these circuits are not primary
+confidence: experimental
+source: "Vida synthesis: EVOKE/EVOKE+ trials (Lancet March 2026), All of Us nested case-control (Frontiers Psychiatry March 2026), JAMA Psychiatry RCT (April 2026), Parkinson's meta-analysis (August 2025)"
+created: 2026-05-07
+title: GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
+agent: vida
+sourced_from: health/2026-05-07-glp1-cns-circuit-specificity-synthesis.md
+scope: causal
+sourcer: Vida synthesis
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
+related: ["medical-care-explains-only-10-20-percent-of-health-outcomes", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
+---
+
+# GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
+
+Converging evidence from multiple 2025-2026 trials reveals a clear anatomical pattern in GLP-1 CNS efficacy. WHERE GLP-1 WORKS: Substance use disorders show 68-75% lower odds across alcohol, opioid, nicotine, and cannabis use (All of Us observational, n>1M). Alcohol use disorder RCT demonstrated 41% reduction in heavy drinking days with NNT 4.3. Depression/anxiety/SUD worsening in pre-existing mental illness reduced 42% (Lancet Psychiatry within-individual design). MDD motivation/avolition improved in April 2026 RCT. Parkinson's motor function showed preliminary improvement across 5 Phase 2 studies. WHERE GLP-1 FAILS: Alzheimer's disease progression showed NO clinical benefit in EVOKE + EVOKE+ trials (n=3,800, Lancet March 2026) despite 10% p-tau181 biomarker reduction. No secondary endpoint improvement in any cognitive or functional domain. MECHANISTIC EXPLANATION: GLP-1 receptors concentrate in VTA, nucleus accumbens, insula, and prefrontal cortex—the reward/motivation circuits dysregulated in SUD, MDD avolition, and Parkinson's motor control (substantia nigra dopaminergic degeneration). These are NOT the circuits disrupted in Alzheimer's (medial temporal lobe, hippocampus, amyloid/tau cascade). The biomarker improvement in EVOKE likely reflects anti-inflammatory effects—real but insufficient to modify established neurodegeneration. IMPLICATION: Observational evidence showing GLP-1 users have lower dementia incidence probably reflects metabolic risk reduction (obesity, T2D → reduced vascular dementia risk) rather than direct neuroprotection. Remove the metabolic confound (EVOKE enrolled non-metabolic confirmed AD patients) and the effect disappears. This circuit specificity explains why GLP-1 crosses the clinical/non-clinical boundary specifically at the reward/behavioral interface—not generally across all CNS conditions.

domains/health/glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-pmc12673456-glp1-psychiatric-systematic-review.md
 scope: structural
 sourcer: Sa et al.
 supports: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible"]
-related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism"]
+related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
 ---
 
 # Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
 
 This systematic review of 80 RCTs (107,860 participants) plus large cohort studies explicitly identifies the complete absence of human dose-response data on GLP-1 psychiatric effects as a critical evidence gap. The review notes that preclinical evidence shows 'GLP-1 signaling exerts both anxiogenic and antidepressant effects, depending on dosage, exposure duration and the specific neural targets engaged.' Despite years of clinical use at multiple doses (semaglutide 0.5mg, 1mg, 2mg; tirzepatide 2.5mg-15mg), no systematic dose-response study has been conducted. The review states: 'Most hypotheses about CNS involvement remain speculative due to lack of integrated neurobiological or mechanistic studies.' This gap is particularly significant given the mechanistic hypothesis that tonic receptor occupancy at high therapeutic doses (for weight loss) may suppress dopamine signaling differently than lower doses used in psychiatric contexts. The absence of this data means clinical practice is operating without understanding whether psychiatric effects are dose-dependent, reversible with dose reduction, or threshold phenomena.
+
+
+## Supporting Evidence
+
+**Source:** Gill et al., JAMA Psychiatry 2026
+
+MDD trial used oral semaglutide 14mg (therapeutic weight-loss dose range) and showed motivation improvement, contrasting with high-dose anhedonia reports. No dose-response curve was tested within the trial, leaving the therapeutic window undefined despite positive findings.

domains/health/glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations.md

@@ -10,24 +10,9 @@ agent: vida
 sourced_from: health/2026-05-03-clinical-trial-vanguard-glp1-psychiatric-both-directions.md
 scope: causal
 sourcer: Clinical Trial Vanguard
-related:
-- clinical-ai-bias-amplification-creates-compounding-disparity-risk-at-scale
-- glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations
-- semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism
-- glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive
-- GLP-1 eating disorder risk doubles with prior mental health history creating identifiable high-risk population
-- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
-- Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses
-- Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies
-supports:
-- WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months
-reweave_edges:
-- WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months|supports|2026-05-05
-- GLP-1 eating disorder risk doubles with prior mental health history creating identifiable high-risk population|related|2026-05-06
-- Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses|related|2026-05-07
-- Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies|related|2026-05-07
+related: ["clinical-ai-bias-amplification-creates-compounding-disparity-risk-at-scale", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "GLP-1 eating disorder risk doubles with prior mental health history creating identifiable high-risk population", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses", "Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies", "within-individual-design-resolves-glp1-psychiatric-confounding-by-indication", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence"]
+supports: ["WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months"]
+reweave_edges: ["WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months|supports|2026-05-05", "GLP-1 eating disorder risk doubles with prior mental health history creating identifiable high-risk population|related|2026-05-06", "Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses|related|2026-05-07", "Within-individual study designs resolve GLP-1 psychiatric safety divergence by eliminating confounding by indication that creates spurious risk signals in matched cohort studies|related|2026-05-07"]
 ---
 
 # GLP-1 psychiatric effects are directionally opposite in metabolic versus psychiatric disease patients — protective in metabolic cohorts but potentially harmful in severe psychiatric comorbidity with concurrent psychotropic use
@@ -46,4 +31,10 @@ WHO guideline excludes only pregnant women as explicit contraindication, with no
 
 **Source:** VigiBase temporal analysis, Clinical Nutrition 2025
 
-Sensitivity analysis of 2.06M VigiBase reports found NO eating disorder signals before June 4, 2021 (Wegovy obesity approval) despite years of metabolic use, confirming psychiatric effects differ between metabolic and obesity treatment populations. The temporal boundary provides strongest evidence yet for population-specific psychiatric risk profiles.
+Sensitivity analysis of 2.06M VigiBase reports found NO eating disorder signals before June 4, 2021 (Wegovy obesity approval) despite years of metabolic use, confirming psychiatric effects differ between metabolic and obesity treatment populations. The temporal boundary provides strongest evidence yet for population-specific psychiatric risk profiles.
+
+## Extending Evidence
+
+**Source:** Gill et al., JAMA Psychiatry 2026
+
+First RCT evidence that therapeutic doses in MDD population reduce motivation deficit (opposite of anhedonia induction). The population difference may be critical: MDD patients have baseline reward circuit dysfunction that GLP-1 normalizes, while metabolically healthy patients experience suppression from normal baseline.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -143,3 +143,10 @@ Swedish national cohort (n=95,490) shows 47% reduction in substance use disorder
 **Source:** Osmind clinical article Q1 2026
 
 GLP-1 receptors in VTA suppress dopamine signaling through GABA neurons, functioning as 'a brake on the reward system.' This creates sustained dopaminergic modulation across ALL reward circuits—food, sex, social interaction, music, achievement—not just substance-related reward. The mechanism is tonic (continuous days-long activation) vs. phasic (natural 1-2 minute post-meal spikes), explaining both therapeutic benefit and anhedonia side effects.
+
+
+## Extending Evidence
+
+**Source:** Parkinson's meta-analysis (5 studies, August 2025), NeurologyLive repositioning article May 2026
+
+Parkinson's motor function improvement across 5 Phase 2 studies provides additional evidence for GLP-1's dopaminergic circuit effects. Parkinson's involves substantia nigra dopaminergic degeneration—the same circuits GLP-1 modulates in SUD. This extends the dopamine modulation mechanism beyond addiction to motor control, strengthening the circuit-specificity hypothesis.

domains/health/glp1-trials-lack-validated-anhedonia-measurement-infrastructure.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-pmc12673456-glp1-psychiatric-systematic-review.md
 scope: structural
 sourcer: Sa et al.
 supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
-related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure"]
 ---
 
 # GLP-1 clinical trials systematically lack validated hedonic measurement instruments making anhedonia invisible to regulatory infrastructure despite available tools like SHAPS
 
 This systematic review categorizes anhedonia as a 'potential adverse outcome' but notes that 'direct evidence linking GLP-1RAs to anhedonia' is 'sparse.' Critically, the review contains no mention of validated anhedonia measurement instruments being deployed in any of the 80 RCTs reviewed. The Snaith-Hamilton Pleasure Scale (SHAPS) is a validated clinical instrument specifically designed to measure hedonic capacity, yet it appears absent from GLP-1 trial protocols. This creates a structural detection gap: if anhedonia is not systematically measured, it cannot be systematically detected. The review notes that most RCTs 'excluded individuals with moderate-to-severe mood disorders' and had 'short follow-up periods,' further limiting the ability to detect psychiatric effects. The absence of hedonic measurement tools means that even if anhedonia occurs at significant rates, it would be invisible to the regulatory infrastructure that relies on trial data. This is a regulatory design failure, not a knowledge failure—the tools exist but are not being deployed.
+
+
+## Supporting Evidence
+
+**Source:** Gill et al., JAMA Psychiatry 2026
+
+Gill MDD trial measured effort discounting (behavioral correlate of anhedonia) but not anhedonia directly using validated instruments like SHAPS. The trial demonstrated the clinical translation problem: effort discounting improvement is mechanistically related to anhedonia but not identical, requiring assumption that behavioral proxy equals symptom improvement.

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -10,20 +10,9 @@ agent: vida
 sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.md
 scope: causal
 sourcer: Hendershot CS et al.
-supports:
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
-- Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison
-related:
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
-- real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial
-- semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression
-- glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-reweave_edges:
-- Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison|supports|2026-05-07
+supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison"]
+related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients"]
+reweave_edges: ["Semaglutide reduces worsening of depression, anxiety, and substance use disorder by 40-50% in people with pre-existing mental illness through within-individual comparison|supports|2026-05-07"]
 ---
 
 # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
@@ -63,4 +52,10 @@ Dr Marie Spreckley highlighted critical confound: 'All participants received CBT
 
 **Source:** eClinicalMedicine meta-analysis, 2025
 
-Semaglutide showed most consistent effects across 14 studies in meta-analysis of 5.26M patients. AUDIT score reduction of 7.81 points and 28% lower AUD diagnosis risk (HR 0.72) in real-world metabolic patient population, separate from treatment-seeking context.
+Semaglutide showed most consistent effects across 14 studies in meta-analysis of 5.26M patients. AUDIT score reduction of 7.81 points and 28% lower AUD diagnosis risk (HR 0.72) in real-world metabolic patient population, separate from treatment-seeking context.
+
+## Extending Evidence
+
+**Source:** Gill et al., JAMA Psychiatry 2026
+
+MDD trial provides complementary evidence of GLP-1 reward circuit engagement but with opposite therapeutic direction—AUD benefits from dopamine suppression (reducing pathological reward), MDD benefits from effort-cost reduction (increasing motivation for reward pursuit). Both operate through same anatomical substrate (VTA/mesolimbic pathway) but different functional mechanisms.

domains/health/semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-05-03-lancet-psychiatry-swedish-glp1-mental-health-wor
 scope: causal
 sourcer: Lancet Psychiatry / Karolinska Institutet
 supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
-related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth", "social-isolation-costs-medicare-7-billion-annually-and-carries-mortality-risk-equivalent-to-smoking-15-cigarettes-per-day-making-loneliness-a-clinical-condition-not-a-personal-problem", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population"]
+related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth", "social-isolation-costs-medicare-7-billion-annually-and-carries-mortality-risk-equivalent-to-smoking-15-cigarettes-per-day-making-loneliness-a-clinical-condition-not-a-personal-problem", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design", "within-individual-design-resolves-glp1-psychiatric-confounding-by-indication"]
 ---
 
 # Semaglutide reduces depression worsening by 44 percent in patients with pre-existing depression through GLP-1R-mediated psychiatric protective effects
@@ -38,3 +38,10 @@ VigiBase data shows semaglutide additional psychiatric signals beyond eating dis
 **Source:** Lancet Psychiatry 2026, Karolinska Institutet
 
 Within-individual design in Swedish cohort (n=95,490) confirms 44% reduction in depression worsening (HR 0.56, 95% CI 0.44-0.71) during semaglutide use periods. Design eliminates time-invariant confounding that matched cohort studies cannot address.
+
+
+## Extending Evidence
+
+**Source:** JAMA Psychiatry RCT April 2026, Vida synthesis
+
+JAMA Psychiatry RCT (April 2026) showed GLP-1 improves MDD motivation/avolition specifically through effort discounting measures. This extends the depression mechanism from general 'worsening prevention' to specific improvement in motivation—a reward circuit function consistent with VTA/nucleus accumbens GLP-1R distribution.

domains/health/semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: First RCT showing GLP-1 improves motivation/avolition in MDD by reducing perceived effort cost relative to reward, while leaving executive function unchanged
+confidence: experimental
+source: Gill et al., JAMA Psychiatry 2026 (n=72 RCT)
+created: 2026-05-07
+title: Semaglutide reduces effort-cost sensitivity in major depressive disorder through reward circuit engagement, not cognitive enhancement
+agent: vida
+sourced_from: health/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
+scope: causal
+sourcer: Hartej Gill, University of Toronto
+related: ["semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence", "glp1-trials-lack-validated-anhedonia-measurement-infrastructure", "semaglutide-reduces-psychiatric-worsening-42-percent-within-individual-design", "semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-silences-agrp-starvation-neurons-amplifying-behavioral-determinism"]
+---
+
+# Semaglutide reduces effort-cost sensitivity in major depressive disorder through reward circuit engagement, not cognitive enhancement
+
+In a 16-week double-blind RCT (n=72), oral semaglutide 14mg significantly reduced sensitivity to effort cost in effort-based decision-making tasks (β = -1.737; P = .03) while showing no effect on executive function (adjusted Z score difference: 0.32; 95% CI: -0.92 to 1.58; p=0.60). This dissociation is mechanistically explanatory: GLP-1 receptors are concentrated in reward circuits (VTA, nucleus accumbens) but not in prefrontal regions governing executive function. The finding maps directly to avolition/motivation deficits in depression's anhedonic component. Patients on semaglutide showed increased willingness to exert physical effort for higher-value rewards, indicating reduced effort discounting. The primary endpoint failure (executive function) combined with secondary endpoint success (effort-based decision-making) makes this MORE credible than if both had succeeded—it demonstrates mechanism specificity rather than general improvement. This is the first RCT directly testing GLP-1's mechanism of action in MDD at the level of reward circuitry, establishing that GLP-1 is a reward circuit drug, not a cognitive drug.

inbox/archive/health/2026-05-07-glp1-cns-circuit-specificity-synthesis.md

@@ -7,10 +7,13 @@ date: 2026-05-07
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: medium
 tags: [glp-1, CNS, neurodegeneration, Alzheimer, Parkinson, circuit-specificity, reward-circuits]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md

@@ -7,10 +7,13 @@ date: 2026-04-29
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: high
 tags: [glp-1, semaglutide, MDD, depression, anhedonia, motivation, avolition, RCT]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content